Report on improving safety of phase 1 clinical trials

The group established to make recommendations on improving the safety of phase 1 clinical trials, has published its final report. The independent Expert Scientific Group (ESG) was convened by the Secretary of State for Health to examine trials involving new types of drugs, following adverse reactions experienced by participants in the clinical trial of the drug known as TGN1412 earlier this year.